Close

Cellipont and Diakonos to develop cell therapy for glioblastoma

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Cellipont Bioservices has signed an agreement with Diakonos Oncology for the development of DOC1021, a cell therapy to treat glioblastoma multiforme (GBM).

The parties will carry out the process development and current good manufacturing practice (cGMP) production of DOC1021 for GBM and other cancers.

Diakonos CEO Mike Wicks stated: “As DOC1021 is personalised to each patient, it was critical to find a CDMO [contract development and manufacturing organisation] partner that could not only help commercialise this incredibly promising treatment but exceed our quality standards for each and every patient.

“We could not be happier to find that partner in Cellipont, and we look forward to changing patient outcomes in GBM as well as other cancer indications.”

An autologous dendritic cell vaccine, DOC1021 stimulates a natural anti-viral immune response against tumours.

Based on the promising safety and efficacy data from a Phase I clinical trial, the US Food and Drug Administration granted fast-track designation for the vaccine.

Latest stories

Related stories

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back